Nutriband Inc. (NTRB) Insider Trading Activity

NASDAQ$3.58
Market Cap
$43.52M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
701 of 870
Rank in Industry
407 of 505

NTRB Insider Trading Activity

NTRB Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
Sells
$0
0

Related Transactions

About Nutriband Inc.

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Insider Activity of Nutriband Inc.

Over the last 12 months, insiders at Nutriband Inc. have bought $0 and sold $0 worth of Nutriband Inc. stock.

On average, over the past 5 years, insiders at Nutriband Inc. have bought $4,030 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,000 shares for transaction amount of $4,030 was made by MELNIK SERGUEI (Chairman and President) on 2022‑02‑24.

List of Insider Buy and Sell Transactions, Nutriband Inc.

2022-02-24PurchaseMELNIK SERGUEIChairman and President
1,000
0.0125%
$4.03
$4,030
+9.14%
Total: 1

Insider Historical Profitability

9.14%
MELNIK SERGUEIChairman and President
633000
5.2073%
$2.27M10
+9.14%

Historical Insider Profitability vs. Competitors

$155,630,608
79
-24.53%
$54.18M
$693,326
47
-16.18%
$49.93M
$95,303,339
30
-13.78%
$34.69M
$2,983,776
25
-16.47%
$33.5M
$523,320
24
94.37%
$34.12M
$241,165
22
-16.72%
$33.88M
$226,127
22
-27.62%
$48.55M
$351,813
19
21.51%
$32.46M
$3,556,951
18
9.64%
$41.07M
$31,610,161
9
-73.83%
$46.07M
$189,648
9
-52.20%
$32.31M
$208,889
5
44.22%
$46.08M
$104,699
5
-12.61%
$38.49M
$5,306,958
5
11.70%
$44.15M
$657,791
4
-52.05%
$37.18M
$67,369,250
3
-22.09%
$45.13M
Nutriband Inc.
(NTRB)
$4,030
1
9.14%
$43.52M
$4,999,995
1
-67.50%
$48.99M
$150,000
1
5.48%
$45.8M

NTRB Institutional Investors: Active Positions

Increased Positions5+17.86%17,605+4.71%
Decreased Positions9-32.14%27,180-7.27%
New Positions4New17,251New
Sold Out Positions3Sold Out319Sold Out
Total Postitions24-14.29%364,194-2.56%

NTRB Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$898.001.69%202,738+3,111+1.56%2025-09-30
Geode Capital Management, Llc$266.000.5%59,943-3,688-5.8%2025-09-30
State Street Corp$111.000.21%24,96600%2025-09-30
Ubs Group Ag$87.000.16%19,637+19,636+1.96M%2025-09-30
Cetera Investment Advisers$84.000.16%18,900+18,900New2025-09-30
Northern Trust Corp$62.000.12%13,945+2,463+21.45%2025-09-30
Haven Private, Llc$51.000.1%11,52100%2025-09-30
Blackrock, Inc.$37.000.07%8,420+135+1.63%2025-09-30
Osaic Holdings, Inc.$21.000.04%4,85100%2025-09-30
Morgan Stanley$16.000.03%3,50000%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.